Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study seeks to unlock secrets of lung disease resilience

NCT ID NCT05584722

First seen Mar 19, 2026 · Last updated Apr 30, 2026 · Updated 5 times

Summary

This study aims to understand why some people develop pulmonary arterial hypertension (PAH), a severe lung disease, while others with genetic risks do not. Researchers will follow 150 participants, including those with PAH, healthy carriers of a PAH-related gene mutation, and healthy individuals, for up to 32 months. By tracking quality of life, exercise ability, and heart function, they hope to create molecular profiles that predict disease susceptibility and resilience, potentially leading to new treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.